Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Cancer, Breast
Interventions: BIOLOGICAL: Trastuzumab IV|BIOLOGICAL: Trastuzumab SC|BIOLOGICAL: Pertuzumab|DRUG: Docetaxel
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Collaborators: University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit|University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology|University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione|Clirest s.r.l.|Mipharm SpA|Arithmos srl|Temas srl